BMRN trailing returns
BioMarin Pharmaceutical Inc.'s 10-year annualized return is -3.0% per year (-25.9% cumulative). How BioMarin Pharmaceutical Inc. (BMRN) has performed over the last day, week, month and year, over 5, 10 and 20 years, and since inception, through August 13, 2026 — cumulative and annualized, with dividends on or off.
Trailing returns by period#
To 2026-08-13. Annualized (CAGR) for windows of a year or more.
| Period | Path | Annualized | Cumulative |
|---|---|---|---|
| 1 day | — | -2.5% | |
| 1 week | — | +11.5% | |
| 1 month | — | +16.2% | |
| YTD | — | +15.3% | |
| 1 year | +20.5% | +20.5% | |
| 5 years | -1.9% | -9.1% | |
| 10 years | -3.0% | -25.9% | |
| 20 years | +7.9% | +356.7% | |
| Since inception (1999) | +6.3% | +426.9% |
Growth of BMRN#
Actual index level (solid); dashed lines are each window's constant-rate path from start to today.
Methodology#
Trailing returns measure from the closest close about N years before the latest close (2026-08-13). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Total return reinvests dividends (from BMRN's split- and dividend-adjusted closes); price return excludes them. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.
See also: S&P 500 · Nasdaq-100 · Dow Jones · Russell 2000 · US Bond Market · Gold · Silver · Bitcoin · Ethereum
FAQ#
- What is BioMarin Pharmaceutical Inc.'s 10-year return?
- Over the last 10 years, BioMarin Pharmaceutical Inc. (BMRN) returned about -3.0% a year annualized (-25.9% cumulative total return).
- What is BioMarin Pharmaceutical Inc.'s 20-year annualized return?
- Over the last 20 years, BioMarin Pharmaceutical Inc. (BMRN) compounded at about +7.9% a year (+356.7% cumulative).
- What is BioMarin Pharmaceutical Inc.'s return since inception?
- Since 1999, BioMarin Pharmaceutical Inc. (BMRN) has compounded at about +6.3% a year — +426.9% in total.